The grant covers Merrimack’s three clinical stage cancer programs, MM-121, a new, first-in-class ErbB3 (HER3) antagonist, MM-111, a new bi-specific antibody targeting ErbB2/ErbB3 (HER2/HER3) and MM-398, a nanoliposomal formulation of irinotecan, along with three preclinical and four research stage cancer programs.
Merrimack president and CEO Robert Mulroy said that they were grateful for this grant from the Department of Health and Human Services.
"Merrimack will use the grants to continue to advance our therapeutic and diagnostic product candidates in an effort to improve the quality of care for cancer patients," Mulroy said.
QTDP is a grant program created as part of the Patient Protection and Affordable Care Act of 2010 to advance research in areas of unmet medical need.